

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

| | |
|--|-----------|
| OMB APPROVAL | |
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response... | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | |
|--|---|--|
| 1. Name and Address of Reporting Person Slakter Jason Scott | 2. Issuer Name and Ticker or Trading Symbol Ohr Pharmaceutical Inc [OHRP] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Executive Officer |
| (Last) (First) (Middle) C/O OHR PHARMACEUTICAL, INC., 800 THIRD AVE., 11TH FLOOR | 3. Date of Earliest Transaction (Month/Day/Year) 11/02/2015 | |
| (Street) NEW YORK, NY 10022 | 4. If Amendment, Date Original Filed(Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person |
| (City) (State) (Zip) | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | |

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--------------------------------------|--|--------------------------------|---|---|------------|-----------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock, par value \$0.0001 per share | 11/02/2015 | | P | | 500 | A | \$ 2.97 | 65,073 | D | |
| Common Stock, par value \$0.0001 per share | 11/02/2015 | | P | | 300 | A | \$ 2.9799 | 65,373 | D | |
| Common Stock, par value \$0.0001 per share | 11/02/2015 | | P | | 400 | A | \$ 2.98 | 65,773 | D | |
| Common Stock, par value \$0.0001 per share | 11/02/2015 | | P | | 750 | A | \$ 2.9897 | 66,523 | D | |
| Common Stock, par value \$0.0001 per share | 11/02/2015 | | P | | 1,800 | A | \$ 2.9899 | 68,323 | D | |
| Common Stock, par value \$0.0001 per share | 11/02/2015 | | P | | 2,600 | A | \$ 2.99 | 70,923 | D | |
| Common Stock, par value \$0.0001 per share | 11/02/2015 | | P | | 700 | A | \$ 2.9997 | 71,623 | D | |
| Common Stock, par value \$0.0001 per share | 11/02/2015 | | P | | 300 | A | \$ 2.9999 | 71,923 | D | |
| Common Stock, par value \$0.0001 per share | 11/02/2015 | | P | | 2,600 | A | \$ 3 | 74,523 | D | |
| Common Stock, par value \$0.0001 per share | 11/02/2015 | | P | | 1,300 | A | \$ 3.01 | 75,823 | D | |
| Common Stock, par value \$0.0001 per share | 11/02/2015 | | P | | 200 | A | \$ 3.0197 | 76,023 | D | |
| Common Stock, par value \$0.0001 per share | 11/02/2015 | | P | | 200 | A | \$ 3.02 | 76,223 | D | |
| Common Stock, par value \$0.0001 per share | 11/02/2015 | | P | | 200 | A | \$ 3.0297 | 76,423 | D | |
| Common Stock, par value \$0.0001 per share | 11/02/2015 | | P | | 1,400 | A | \$ 3.03 | 77,823 | D | |
| Common Stock, par value \$0.0001 per share | 11/03/2015 | | P | | 100 | A | \$ 3.01 | 77,923 | D | |
| Common Stock, par value \$0.0001 per share | | | | | | | | 425,505 | I | By SKS Ocular, LLC |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

| |
|--|
| |
|--|


Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|-----|-----|--|-----------------|---|----------------------------|--|--|--|--|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| | | | | | | | | | | | | | | | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|-------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Slakter Jason Scott C/O OHR PHARMACEUTICAL, INC. 800 THIRD AVE., 11TH FLOOR NEW YORK, NY 10022 | X | | Chief Executive Officer | |

Signatures

| | |
|--|------------|
| /s/ Jason Scott Slakter | 11/04/2015 |
|  | Date |

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.